Bile Duct Adenocarcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2024-04-26
Clinical Trial Update: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma [Phase 2]
Phase 2 trial evaluating Disitamab Vedotin in combination with Cadonilimab for HER2-mutant non-resectable biliary tract adenocarcinoma, curr…